Scope
AAOS’s December 2023 hip osteoarthritis guideline addresses conservative symptom treatment, arthroplasty choices, perioperative risk and rehabilitation. It strongly supports appropriate NSAIDs and tranexamic acid, advises against intra-articular hyaluronic acid, and clearly labels several risk and medication statements as limited evidence or consensus. Individual circumstances remain central to surgical decisions.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Choose conservative treatment according to symptoms and contraindications
- Consider physiotherapy for mild-to-moderate symptomatic hip osteoarthritis to reduce pain and improve function. This is a moderate-strength recommendation; it is not a promise that every patient will avoid arthroplasty. [1]
- Use oral NSAIDs for symptomatic pain and functional limitation when not contraindicated. Review renal and cardiovascular risk; the guideline identifies chronic kidney disease and significant cardiac conditions as concerns. [1]
- Oral acetaminophen may be considered when not contraindicated, but this is a workgroup consensus option because evidence is insufficient, rather than an evidence-equivalent replacement for NSAIDs. [1]
- Do not use oral opioids as nonoperative treatment for symptomatic hip osteoarthritis. AAOS presents this as a consensus position in the absence of sufficient supporting evidence. [1]
Set realistic expectations for intra-articular treatments
- Intra-articular corticosteroids may improve pain and function in the short term. The recommendation is moderate strength; discuss the risks of infection and rapidly progressive osteoarthritis rather than presenting injection as harmless long-term disease control. [1]
- Do not use intra-articular hyaluronic acid for symptomatic hip osteoarthritis: high-quality evidence does not show pain or functional benefit beyond placebo. [1]
Individualize arthroplasty planning
- Consider tranexamic acid during total hip arthroplasty for symptomatic osteoarthritis to reduce blood loss and transfusion need. The guideline strongly supports this strategy but the summary does not provide a dose or administration protocol. [1]
- For older adults undergoing total hip arthroplasty, consider cemented femoral fixation because it is associated with lower periprosthetic-fracture risk. The evidence is low quality, with the recommendation upgraded to moderate strength. [1]
- Select the surgical approach through its specific benefits and risks rather than assuming one approach is universally preferred. AAOS finds no preferred approach for total hip arthroplasty in symptomatic osteoarthritis. [1]
- Neuraxial anaesthesia may be used to reduce adverse events during hip arthroplasty, but this is a limited-evidence option and needs individual anaesthetic assessment. [1]
Discuss modifiable risks without overstating the evidence
- Explain that elevated BMI may increase arthroplasty complications. Patients with higher BMI may have lower absolute postoperative scores while still achieving a similar degree of improvement in pain, function, satisfaction and quality of life; these are limited-evidence findings. [1]
- Recognize poorly controlled diabetes as a possible risk factor for adverse events after arthroplasty. This is a limited-evidence finding to include in risk discussion and preoperative planning. [1]
- Include tobacco use in preoperative risk assessment because limited evidence links it to increased adverse events after total hip arthroplasty. [1]
- Account for stiff-spine syndrome when discussing postoperative dislocation risk. The workgroup identifies possible increased risk compared with patients without a stiff spine, as a consensus option. [1]
- Consider social circumstances in planning care and support. Limited evidence associates education, income, food access and insurance-related factors with longer stays, greater costs and mortality after arthroplasty. [1]
Plan recovery according to patient needs
- After total hip arthroplasty for symptomatic osteoarthritis, either formal physiotherapy or an unsupervised home-exercise programme is supported. Match the arrangement to the patient rather than requiring formal treatment for everyone. [1]
Limitations and use
- This is not a diagnostic workup, surgical eligibility calculator or complete perioperative protocol. It provides no universal BMI, HbA1c or tobacco-abstinence cutoff.
- Drug doses, contraindication lists, injection technique, thromboprophylaxis and specific rehabilitation prescriptions require separate clinical protocols.
- Limited-evidence and consensus options should not be interpreted as strong comparative proof or automatic reasons to withhold arthroplasty.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Management of Osteoarthritis of the Hip
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAOS
- Resource type
- Clinical practice guideline · House clinical summary
- Source setting
- United States
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.